vTv Therapeutics

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer's disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial. vTv Therapeutics' type II diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator (GKA), for which it has completed enrollment in its Phase IIb clinical trial, and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor (GLP-1r), for which it began enrollment in a Phase II clinical trial. The Company has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.

Company Growth (employees)
Type
Public
HQ
High Point, US
Founded
1998
Size (employees)
51 (est)
vTv Therapeutics was founded in 1998 and is headquartered in High Point, US

vTv Therapeutics Office Locations

vTv Therapeutics has an office in High Point
High Point, US (HQ)
4170 Mendenhall Oaks Pkwy

vTv Therapeutics Data and Metrics

vTv Therapeutics Financial Metrics

vTv Therapeutics's revenue was reported to be $30 k in Q1, 2017
USD

Revenue (Q1, 2017)

30 k

EBIT (Q1, 2017)

(13.8 m)

Market capitalization (15-Aug-2017)

47.8 m

Cash (31-Mar-2017)

45.2 m
vTv Therapeutics's current market capitalization is $47.8 m.
USDFY, 2015FY, 2016

Revenue

519 k634 k

Revenue growth, %

22%

R&D expense

27.2 m45 m

General and administrative expense

9.1 m9.9 m

Operating expense total

38.7 m55.7 m

EBIT

(38.1 m)(55 m)

EBIT margin, %

(7349%)(8678%)

Interest expense

(68 k)(398 k)

Interest income

87 k

Net Income

(55.4 m)
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

133 k376 k182 k38 k30 k

R&D expense

6.6 m11.1 m12.1 m10.6 m11 m

General and administrative expense

2.4 m2.6 m2.7 m2.4 m2.8 m

Operating expense total

9 m13.7 m14.7 m13 m13.8 m

EBIT

(9.4 m)(13.5 m)(14.6 m)(13.5 m)(13.8 m)

EBIT margin, %

(7098%)(3601%)(8043%)(35600%)(45847%)

Interest expense

21 k21 k21 k(559 k)

Interest income

4 k21 k21 k21 k27 k

Pre tax profit

(9.8 m)
USDFY, 2015FY, 2016

Cash

88 m51.5 m

Inventories

1.1 m612 k

Current Assets

89.2 m52.1 m

PP&E

624 k444 k

Total Assets

91.5 m54.5 m

Accounts Payable

6.6 m11.4 m

Total Debt

22.1 m

Current Liabilities

7.7 m11.4 m

Total Liabilities

22.9 m

Additional Paid-in Capital

117.7 m124.2 m

Retained Earnings

(196 m)(215.5 m)

Debt to Assets Ratio

0.4 x
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

97 m75.5 m63.8 m51.1 m45.2 m

Current Assets

97.8 m77.1 m64.3 m52.1 m45.9 m

PP&E

669 k545 k561 k493 k426 k

Total Assets

100.2 m79.6 m66.8 m54.7 m48.3 m

Accounts Payable

5.2 m8 m9.5 m10.2 m11.1 m

Current Liabilities

6.1 m8.7 m9.8 m10.6 m11.1 m

Additional Paid-in Capital

117.1 m119.5 m122.1 m122.8 m125.1 m

Retained Earnings

(211.6 m)(182.9 m)(202 m)(234.4 m)(248.9 m)
USDFY, 2015FY, 2016

Depreciation and Amortization

501 k265 k

Accounts Receivable

(69 k)69 k

Inventories

5.5 m

Accounts Payable

2.9 m4.8 m

Cash From Operating Activities

(36.9 m)(48.2 m)

Purchases of PP&E

(104 k)(87 k)

Cash From Investing Activities

(79 k)(83 k)

Long-term Borrowings

(89 k)

Cash From Financing Activities

123.6 m11.8 m

Interest Paid

75 k242 k
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Accounts Payable

5.2 m8 m9.5 m10.2 m11.1 m
USDY, 2017

Revenue/Employee

588.2

vTv Therapeutics Operating Metrics

FY, 2016

Phase III Trials

1

Phase II Trials

2

Phase I Trials

2

vTv Therapeutics Market Value History

Traffic Overview of vTv Therapeutics

vTv Therapeutics Company Life and Culture

You may also be interested in